Business · 31/08/2010Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for PRISTIQ Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for PRISTIQ, a human drug product, as required by law, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Health and Human ServicesOpen original release →